AMEX · Financial Statements

Serina Therapeutics, Inc. (SER) Revenue, Earnings & Financial Statements

$1.37 AMEX: SER Market Cap $20.47M

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Serina Therapeutics, Inc. most recently reported annual revenue of $0, a net loss of $19.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Serina Therapeutics, Inc.: Revenue fell from $2.0M in 2016 to $0 in 2025, a change of -100.0% over 9 years; net profit was positive in 1 of 10 reported years; operating margin moved from -764.6% to -30442.9%, a shift of -29678.2 percentage points; the most recent year shows a net loss of $19.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$2.0M$1.0M$1.0M$2.0M$0$3.0M$1.0M$3.0M$0$0
Operating Expenses$14.0M$10.0M$12.0M$14.0M$10.0M$5.0M$3.0M$6.0M$17.0M$24.0M
Operating Profit−$13.0M−$8.0M−$10.0M−$13.0M−$10.0M−$2.0M−$2.0M−$3.0M−$17.0M−$24.0M
Operating Margin-764.6%-599.5%-748.2%-726.8%-19272.2%-47.1%-454.1%-99.2%-30442.9%—
Other Income−$5.0M$2.0M$3.0M$0$0$0$0$8.0M$6.0M$5.0M
Interest$0$0$0$0$0$0$0$1.0M$1.0M$0
Depreciation$1.0M$1.0M$1.0M$1.0M$1.0M$0$0$0$0$0
Profit Before Tax−$17.0M−$7.0M−$8.0M−$12.0M−$10.0M−$1.0M−$3.0M$5.0M−$11.0M−$19.0M
Tax rate (%)0.0%0.0%0.0%-1.2%0.0%0.0%0.0%0.0%0.0%-0.1%
Net Profit−$15.0M−$7.0M−$8.0M−$12.0M−$11.0M−$1.0M−$3.0M$5.0M−$11.0M−$19.0M
EPS−$15.21−$6.46−$7.56−$11.47−$10.14−$0.59−$2.49$0.63−$1.51−$1.91

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$3.0M$0$0$0$0$0$0$0$0$0$0$0
Operating Expenses$3.0M$2.0M$4.0M$5.0M$6.0M$6.0M$6.0M$6.0M$6.0M$6.0M$7.0M$8.0M
Operating Profit$0−$2.0M−$4.0M−$5.0M−$6.0M−$6.0M−$6.0M−$6.0M−$6.0M−$6.0M−$7.0M−$8.0M
Operating Margin7.8%-46420.0%—-37942.9%39635.7%—-4280.8%————-6288.8%
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax$1.0M−$15.0M$5.0M$1.0M−$3.0M−$5.0M−$6.0M−$5.0M−$3.0M−$7.0M−$6.0M−$8.0M
Tax rate (%)0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%-0.5%-0.1%0.0%0.0%
Net Profit$1.0M−$15.0M$5.0M$1.0M−$3.0M−$5.0M−$6.0M−$5.0M−$3.0M−$7.0M−$6.0M−$8.0M
EPS$0.44−$5.38$0.51$0.13−$0.25−$0.49−$0.64−$0.44−$0.31−$0.58−$0.55−$0.31

Over the 10 years reported for Serina Therapeutics, Inc., cash stood at $3.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 1.50 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$3.0M$10.0M$11.0M$7.0M$4.0M$3.0M$3.0M$9.0M$7.0M$7.0M
Current Assets$1.0M$8.0M$8.0M$4.0M$2.0M$2.0M$2.0M$8.0M$6.0M$6.0M
Cash$0$7.0M$7.0M$2.0M$1.0M$1.0M$1.0M$8.0M$4.0M$3.0M
Inventory$0$0$0$0$0$0$0$0$0$0
Receivables$0$0$0$0$0$0$0$0$0$0
Fixed Assets$0$0$0$1.0M$0$0$0$1.0M$1.0M$1.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$0$0$0$0$0$0$0$0$0$0
Other Assets$0$0$0$0$0$0$0$0$0$0
Total Liabilities$26.0M$1.0M$2.0M$5.0M$9.0M$15.0M$21.0M$41.0M$6.0M$7.0M
Current Liabilities$26.0M$1.0M$2.0M$3.0M$5.0M$9.0M$10.0M$1.0M$2.0M$4.0M
Borrowings$0$0$0$2.0M$6.0M$13.0M$18.0M$3.0M$0$0
Other Liabilities$26.0M$1.0M$2.0M$3.0M$3.0M$2.0M$2.0M$38.0M$6.0M$7.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves−$23.0M$7.0M$7.0M$2.0M−$5.0M−$12.0M−$17.0M−$32.0M$1.0M$0

For Serina Therapeutics, Inc., operating cash flow was positive in 0 of 10 reported years; free cash flow in the latest year was negative at $18.0M; free cash flow was positive in 0 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow−$8.0M−$6.0M−$8.0M−$10.0M−$8.0M−$2.0M−$2.0M−$2.0M−$17.0M−$18.0M
Investing Cash Flow$0$0−$1.0M−$1.0M$0$1.0M$1.0M−$1.0M$0$0
Financing Cash Flow$5.0M$1.0M$0$0$0$1.0M$0$0$5.0M$0
Net Cash Flow−$1.0M$7.0M−$1.0M−$4.0M−$2.0M$0$0$7.0M−$4.0M−$1.0M
Free Cash Flow−$8.0M−$6.0M−$10.0M−$11.0M−$8.0M−$2.0M−$2.0M−$3.0M−$17.0M−$18.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.12
EV / EBITDA-0.19
FCF Yield-109.41%
Quick Ratio4.62
Interest Coverage-65.22
Return 1Y-64.54%
Return 3Y-93.51%
Return 5Y-94.81%

Serina Therapeutics, Inc. (SER) financials — frequently asked questions

What is Serina Therapeutics, Inc.'s annual revenue?

Serina Therapeutics, Inc. (SER) reported annual revenue of $0 in its most recent fiscal year.

What is Serina Therapeutics, Inc.'s net profit?

Serina Therapeutics, Inc. (SER) reported a net loss of $19.0M in its most recent fiscal year.

What is SER EV/EBITDA?

Serina Therapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -0.19. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Revenue and earnings of other Biotechnology stocks

VRTX revenue $12.1BREGN revenue $14.3BMRNA revenue $1.9BRVMD financialsROIV revenue $8.0MINSM revenue $606.0MUTHR revenue $3.2BINCY revenue $5.1BALNY revenue $3.7BASND revenue $692.0MAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
SER Overview SER Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.